OG217SC

Shares of Novo Nordisk A/S (NYSE: NVO) were trading higher by more than 4 percent Friday morning after the company announced positive results from a phase 2 FDA trial. Novo Nordisk announced that it "has successfully completed the phase 2 trial for OG217SC; an oral formulation of the long-acting...